This information is intended for US healthcare professionals For patients

Our Mission

At Urovant Sciences, we’ve made it our mission to keep patient health and well-being front and center. In accordance with Urovant’s ongoing research and development efforts, our Medical Affairs team is honored to play a vital role by providing scientific support and to prioritize the resources needed to assist you where and when it matters most for patients.

OAB Prevalence & Economics

Infographic of U.S. map of 35 million people in US affected by overactive bladder

Infographic of U.S. map of 35 million people in US affected by overactive bladder

Infographic of 23% overall prevalence among people age 40 and over

Infographic of 23% overall prevalence among people age 40 and over

Infographic of percentage of woman and menaffected at least sometimes by overactive bladder symptoms

Infographic of percentage of woman and menaffected at least sometimes by overactive bladder symptoms

Infographic of total healthcare dollar cost per year for overactive bladder based on U.S. Medicare claims data

Infographic of total healthcare dollar cost per year for overactive bladder based on U.S. Medicare claims data

OAB Monograph

Icon graphic of human bladder

OAB Syndrome

Overactive Bladder (OAB) is a symptom complex that, while generally not life-threatening, can greatly impact quality of life.

Learn More

Discover Our Pipeline

Icon graphic of flag

Urovant Sciences is currently studying vibegron for an additional indication. Separately, the company initiated a Phase 2 study of a novel gene therapy.

Learn more

* Estimates are based on 23% prevalence rate from the EpiLUTS study and 2018 US Census Bureau population number projections for 2018.

REFERENCES
1. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–1087.
2. US Census Bureau. Age and Sex Composition: 2018. Available at: https://data.census.gov/cedsci/table?q=people%20by%20age%20group&t=Age%20and%20 Sex&tid=ACSST1Y2018.S0101&hidePreview=false. Accessed November 4, 2020.
3. Puckrein G, Walker D, Xu L, Congdon P, Gooch K. The prevalence and forecast prevalence of overactive bladder in the Medicare population. Clin Med Insights Urol. 2019;12. doi:10.1177/1179561119847464

Tell us what interests you

How interested are you in learning more about the following topics?

The role of β3-adrenoreceptor agonists in treating patients with OAB
Comorbidities among patients with OAB
Reducing the potential risk of drug-drug interactions
Clinical burden of OAB
Economic burden of OAB

Success!

We’ve received your completed survey. Thanks for participating.

Close

Thank You.

We’ve received your inquiry. Thank you for contacting Urovant Sciences Medical Affairs. We will contact you shortly.

Close

Take Survey

Welcome to
Urovant Sciences Medical Affairs

This site is intended as an educational resource for U.S. healthcare providers. The content may include information about products or potential uses that have not been approved by the U.S. Food and Drug Administration.

This information is not intended to be promotional or deliver medical advice.

Choose an option:

I’m a U.S. healthcare professional I’m a U.S. patient or caregiver